Bristol-Myers and Seattle Genetics move a promising flagship combo into PhIII
Late last year investigators for Bristol-Myers Squibb $BMY and Seattle Genetics $SGEN turned up at ASH with some stellar pilot data from a Phase I/II combination study matching Opdivo with Adcetris. In addition to a 90% objective response rate in a small group of patients, the team also tracked a 62% complete response rate among treatment-resistant patients for classical Hodgkin lymphoma.
Now the partners want to see if they can get similar results in a pivotal Phase III matchup.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.